Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 05, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 ordinary shares.
- Price per Share: 1,470.41 pence.
- Treasury Shares Held: 129,658,000 shares (post-transaction).
- Shares in Issue: 5,826,286,259 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed the purchase of 1,000,000 shares on December 05, 2005, which are now held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 1,000,000 share repurchase based on the disclosed price of 1,470.41 pence per share.
- Confirm the updated total share count (5,826,286,259 in issue) against subsequent filings to track dilution or further buybacks.
- Review the company's broader capital allocation strategy to understand the context of holding 129,658,000 shares in Treasury.